There were 394 press releases posted in the last 24 hours and 153,394 in the last 365 days.

Nano Vivere: Legions of Nano-robots Target Cancerous Tumors with Precision

Nano Vivere

New nano-robotic agents capable of navigating through the bloodstream to administer a drug with precision by targeting the active cancerous cells of tumors

GUANGZHOU, GUANGDONG, CHINA, June 29, 2018 /EINPresswire.com/ -- Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that researchers have just achieved a spectacular breakthrough in cancer research.
The legions of nanorobotic agents are actually composed of more than 100 million flagellated bacteria and therefore self-propelled and loaded with drugs that move by taking the most direct path between the drug's injection point and the area of the body to cure.
This way of injecting medication ensures the optimal targeting of a tumor and avoids jeopardizing the integrity of organs and surrounding healthy tissues. As a result, the drug dosage that is highly toxic for the human organism could be significantly reduced.
This scientific breakthrough has just been published in an article that notes the results of the research done on mice, which were successfully administered nanorobotic agents into colorectal tumors.
"These legions of nanorobotic agents were actually composed of more than 100 million flagellated bacteria and therefore self-propelled and loaded with drugs that moved by taking the most direct path between the drug's injection point and the area of the body to cure," explains one of the researchers. "The drug's propelling force was enough to travel efficiently and enter deep inside the tumors."
When they enter a tumor, the nanorobotic agents can detect in a wholly autonomous fashion the oxygen-depleted tumor areas, known as hypoxic zones, and deliver the drug to them. This hypoxic zone is created by the substantial consumption of oxygen by rapidly proliferative tumor cells. Hypoxic zones are known to be resistant to most therapies, including radiotherapy.
But gaining access to tumors by taking paths as minute as a red blood cell and crossing complex physiological micro-environments does not come without challenges. So the team used nanotechnology to do it.

About Nano Vivere (ISIN: CN0024013913)

Nano Vivere is a late stage clinical company, pioneering nanomedicine that is following its unique path: a new way to treat patients thanks to nanophysics delivered at the cell’s nucleus. The company’s technology is based on proprietary technologies and patents and it operates worldwide from the headquarters based in Guangzhou. Nano Vivere is led by a highly trained and distinguished team of experts who have demonstrated success in the combined fields medicine, biologics, neuroscience, and nanotechnology along with the specialized business development track record requisite for the launch of cutting-edge medical technologies.

Jackline Tang
Nano Vivere
13057400750
email us here